



CERTIFICATE OF ANALYSIS No.: 2020-2643

CLIENT

Pharmahemp d.o.o., Cesta v Gorice 8 1000 Ljubljana, Slovenija

SAMPLE CBG DROPS 5% - mct oil



| Sample condition: | SUITABLE | Work order: | 2020-104482 | Sample received: | 11/12/2020 |
|-------------------|----------------|--------------|-------------|--------------------|------------------|
| Sample ID: | 205060 | Analysis ID: | 2020_008 | Start of analysis: | 11/12/2020 |
| Sample type: | Viscous liquid | Method ID: | PHL_RPC_12C | End of analysis: | 14/12/2020 |
| Batch No .: | DR05020345B | Method SOP: | MET-002 | Analyst: | Aleksander Jefim |
| | | | | | |

Concentration

| CANNABINOID PROFILE | Concentration [% w/w] | uncertainty [% w/w] | Graphic cannabi |
|-------------------------------|--------------------------|------------------------|--------------------|
| CBDV - Cannabidivarin | 0.109 | 0.020 | |
| CBDA - Cannabidiolic acid | < LOQ | n/a | |
| CBGA - Cannabigerolic acid | < LOQ | n/a | |
| CBG - Cannabigerol | 4.95 | 0.35 | |
| CBD - Cannabidiol | 0.883 | 0.088 | |
| THCV - Tetrahydrocannabivarin | < LOQ | n/a | |
| CBN - Cannabinol | < LOQ | n/a | |
| CBC - Cannabichromene | 0.085 | 0.019 | - I |

Graphic presentation of relative binoid concentration

| | | [,,,,,,,] | |
|---|--------|-----------|---|
| CBDV - Cannabidivarin | 0.109 | 0.020 | L |
| CBDA - Cannabidiolic acid | < LOQ | n/a | |
| CBGA - Cannabigerolic acid | < LOQ | n/a | |
| CBG - Cannabigerol | 4.95 | 0.35 | |
| CBD - Cannabidiol | 0.883 | 0.088 | |
| THCV - Tetrahydrocannabivarin | < LOQ | n/a | |
| CBN - Cannabinol | < LOQ | n/a | |
| CBC - Cannabichromene | 0.085 | 0.019 | I |
| THC - Δ-9-Tetrahydrocannabinol | 0.0376 | 0.0083 | ļ |
| THCA - Δ -9-Tetrahydocannabinolic acid | < LOQ | n/a | |
| 8-THC - Δ-8-Tetrahydrocannabinol * | < LOQ | n/a | |
| CBL - Cannabicyclol * | n/a | n/a | |

Expanded

The results marked by * relate to non-accredited activity.

Units and abbreviations: % w/w = weight percent, < LOQ = below the limit of quantitation (0.03 % w/w), ND = not detected, n/a = not available.

The results given herein apply only to the sample as received. Expanded Uncertainty was calculated using coverage factor k = 2, corresponding to a double standard uncertainty and characterizes the interval value in which it is possible to expect the real value with a probability of 95%. This is stated according to the ISO/IEC Guide 98-3.

Total or partial reproduction of this document is not allowed without the permit od PharmaHemp d.o.o. The document does not substitute any other legal document.

Date issued:

14/12/2020

End of Certificate

Approved by: VUN

mag. Malko Dragan Analytical Laboratory Manager

Authorized by:

dr. Boštjan Jančar Chief Technology Officer